OBJECTIVES: The Clinical Global Impression-Schizophrenia Scale was designed to assess severity and treatment response in subjects with schizophrenia involved in naturalistic studies and daily clinical practice. The objective of this study is to validate the Portuguese version of the Clinical Global Impression-Schizophrenia Scale in Brazil by assessing its psychometric properties. METHOD: Cross-sectional validation study of the Portuguese version of the Clinical Global Impression-Schizophrenia Scale, tested in outpatients and inpatients with schizophrenia (DSM-IV, ICD-10) from 6 centers in Brazil. Concurrent validity and sensitivity to change were assessed by comparison with the Positive and Negative Syndrome Scale, which is considered the gold standard tool to evaluate patients with schizophrenia. Interrater reliability was evaluated by intraclass correlation coefficients (ICC) calculated based on the scoring of two concomitant raters. RESULTS: 70 inpatients and 70 outpatients were evaluated. Total Clinical Global Impression-Schizophrenia Scale and Positive and Negative Syndrome Scale scores were highly correlated (r=0.79; p<0.01). Positive (r=0.86), negative (r=0.79), depressive (r=0.66) and cognitive (r=0.75) symptoms subscale scores were also correlated between both scales (p<0.01). Sensitivity to change was significantly correlated between the Clinical Global Impression-Schizophrenia Scale and Positive and Negative Syndrome Scale (r=0.73; p<0.01). Interrater reliability was substantial for positive symptoms and total scores of the Clinical Global Impression-Schizophrenia Scale (ICC=0.81 and 0.73), and moderate for negative, depressive, and cognitive symptoms score (0.64, 0.67 and 0.63, respectively). CONCLUSIONS: The Brazilian version of the Clinical Global Impression-Schizophrenia Scale is a valid and reliable instrument for the assessment of severity and treatment response in schizophrenic inpatient and outpatients.
OBJECTIVES: The Clinical Global Impression-Schizophrenia Scale was designed to assess severity and treatment response in subjects with schizophrenia involved in naturalistic studies and daily clinical practice. The objective of this study is to validate the Portuguese version of the Clinical Global Impression-Schizophrenia Scale in Brazil by assessing its psychometric properties. METHOD: Cross-sectional validation study of the Portuguese version of the Clinical Global Impression-Schizophrenia Scale, tested in outpatients and inpatients with schizophrenia (DSM-IV, ICD-10) from 6 centers in Brazil. Concurrent validity and sensitivity to change were assessed by comparison with the Positive and Negative Syndrome Scale, which is considered the gold standard tool to evaluate patients with schizophrenia. Interrater reliability was evaluated by intraclass correlation coefficients (ICC) calculated based on the scoring of two concomitant raters. RESULTS: 70 inpatients and 70 outpatients were evaluated. Total Clinical Global Impression-Schizophrenia Scale and Positive and Negative Syndrome Scale scores were highly correlated (r=0.79; p<0.01). Positive (r=0.86), negative (r=0.79), depressive (r=0.66) and cognitive (r=0.75) symptoms subscale scores were also correlated between both scales (p<0.01). Sensitivity to change was significantly correlated between the Clinical Global Impression-Schizophrenia Scale and Positive and Negative Syndrome Scale (r=0.73; p<0.01). Interrater reliability was substantial for positive symptoms and total scores of the Clinical Global Impression-Schizophrenia Scale (ICC=0.81 and 0.73), and moderate for negative, depressive, and cognitive symptoms score (0.64, 0.67 and 0.63, respectively). CONCLUSIONS: The Brazilian version of the Clinical Global Impression-Schizophrenia Scale is a valid and reliable instrument for the assessment of severity and treatment response in schizophrenic inpatient and outpatients.
Authors: Cecília R Proença; John C Markowitz; Bruno M Coimbra; Hugo Cogo-Moreira; Mariana R Maciel; Andrea F Mello; Marcelo F Mello Journal: Eur J Psychotraumatol Date: 2022-10-14
Authors: Gisele Huf; Evandro S F Coutinho; Marco A V Ferreira; Silvana Ferreira; Flavia Mello; Clive E Adams Journal: Trials Date: 2011-07-20 Impact factor: 2.279
Authors: Denise Razzouk; Monica Kayo; Aglaé Sousa; Guilherme Gregorio; Hugo Cogo-Moreira; Andrea Alves Cardoso; Jair de Jesus Mari Journal: PLoS One Date: 2015-04-08 Impact factor: 3.240
Authors: E S Gouvea; V K Ota; C Noto; M L Santoro; L M Spindola; P N Moretti; C M Carvalho; G Xavier; A C Rios; J R Sato; M A F Hayashi; E Brietzke; A Gadelha; R A Bressan; Q Cordeiro; S I Belangero Journal: Transl Psychiatry Date: 2016-10-04 Impact factor: 6.222
Authors: Ary Gadelha; Vanessa Kiyomi Ota; Jose Paya Cano; Maria Isabel Melaragno; Marilia A C Smith; Jair de Jesus Mari; Rodrigo A Bressan; Sintia Iole Belangero; Gerome Breen Journal: PLoS One Date: 2012-12-31 Impact factor: 3.240
Authors: Vanessa K Ota; Fernanda T Bellucco; Ary Gadelha; Marcos L Santoro; Cristiano Noto; Denise M Christofolini; Idaiane B Assunção; Karen M Yamada; Andrea K Ribeiro-dos-Santos; Sidney Santos; Jair J Mari; Marília A C Smith; Maria I Melaragno; Rodrigo A Bressan; João R Sato; Andrea P Jackowski; Sintia I Belangero Journal: PLoS One Date: 2014-02-03 Impact factor: 3.240
Authors: Arthur A Berberian; Ary Gadelha; Natália M Dias; Tatiana P Mecca; William E Comfort; Rodrigo A Bressan; Acioly T Lacerda Journal: Braz J Psychiatry Date: 2018-10-22 Impact factor: 2.697
Authors: Arthur A Berberian; Giovanna V Moraes; Ary Gadelha; Elisa Brietzke; Ana O Fonseca; Bruno S Scarpato; Marcella O Vicente; Alessandra G Seabra; Rodrigo A Bressan; Acioly L Lacerda Journal: Braz J Psychiatry Date: 2016-04-19 Impact factor: 2.697